VOLITIONRX LTD (VNRX)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.35-0.09%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · VNRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on executing licensing agreements with diagnostic and liquid biopsy companies to generate upfront milestone payments, royalties, and recurring revenue.
Stated as a priority in 2 of last 2 quarters. Revenue grew from approximately $0.2 million in 2025-Q1 to $1.0 million in 2026-Q1, and first half 2026 revenue was $1.4 million, a 112% increase over the first half of 2025. Management has emphasized expanding licensing agreements to drive milestone and recurring revenue, and the revenue growth trajectory is delivering against this focus.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Discussions with more than a dozen leading diagnostic and liquid biopsy companies to enter licensing agreements and bring revenue.”
“Currently in discussions with more than a dozen leading diagnostic and liquid biopsy companies aiming to enter licensing agreements.”
Implement a plan accepted by NYSE American to regain compliance with listing standards by August 6, 2027.
Newly stated in 2026-Q2. The company received NYSE American acceptance of its compliance plan to regain listing standards by August 6, 2027. No financial metrics directly quantify progress yet, so the trajectory is early stage with management committed to taking reasonable measures to regain compliance.
“NYSE American accepted the Company's plan of compliance to regain listing standards by August 6, 2027.”
Manage capital through equity sales, convertible notes, and debt repayments to support operations and growth.
Stated as a priority in 3 of last 3 quarters. The company raised $1.2 million from equity sales and $4.1 million from share and warrant issuance in 2026-Q2, and $5.4 million from equity sales plus $1.9 million from convertible notes in 2026-Q1. Management has actively managed capital allocation and debt through these financings, showing delivery on this priority.
“Issued senior secured convertible promissory notes and completed equity offerings to raise capital.”
“Received net proceeds from equity sales and convertible note issuances to support operations.”
“Issued senior secured convertible promissory notes and managed debt obligations.”
Pursue strategic agreements and collaborations to enhance product offerings and market reach.
Stated as a priority in 2 of last 2 quarters. The company announced a collaboration with Sysmex Corporation and submitted a clinical manuscript expected to unlock a $5 million milestone payment. These strategic agreements and M&A-related activities show ongoing progress aligned with management's stated priorities.
“Announced collaboration with Sysmex Corporation and submission of clinical manuscript expected to unlock $5 million milestone.”
“Announced submission for peer review of clinical manuscript expected to unlock $5 million milestone payment.”
Over the trailing year it converted 0.39x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
25 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.